For the first time I have ever seen in at least half a dozen years, a major newspaper in the form of The Boston Globe has published an editorial on FDA regulation of stem cells. The editorial, entitled “It should be safety-first on stem cell therapies”, argues that while we should take patient concerns into consideration, it must be safety first on experimental stem cell therapies. I commend them for this editorial and their common sense approach to this hot topic. It’s great that the …Read More
I had fun doing an interview on This Week in Science (TWIS) this week with Dr. Kiki Sanders. The video is below. We talked specifically about CRISPR, designer babies, gene drive, and my new book GMO Sapiens. Check out the book. TWIS is so awesome and I am now going back to watch their older episodes.
The FDA in the past year or so has issued draft guidances on regulation of stem cells that would, if finalized, make it crystal clear that what many American stem cell clinics are selling are unapproved drugs. That would be a good thing for patients who are often being put at risk by many of the clinics. This is the reality no matter what some of the patient advocates who promote the clinics might say. Such finalized FDA regs that unambiguously state that, for …Read More
Update: you can also enter our contest on Twitter using the hashtag #CRISPRback. Do you like contests, words, science, and cash? Enter our new contest. It’s a backronym contest for CRISPR. The author of the best backronym will win a $50 prize paid by me and fame of course as the winner. The judges will be WSJ columnist Ben Zimmer, Senior Editor at MIT Tech Review Antonio Regalado, and myself. A backronym is like an acronym, but flipped around in the sense that you choose words …Read More